Publications by authors named "K Chokephaibulkit"
Unveiling immunity gaps and determining a suitable age for a third dose of the measles-containing vaccine: a strategic approach to accelerating measles elimination.
Lancet Reg Health Southeast Asia
January 2025
Background: In highly measles immunized countries, immunity gaps in adolescents and young adults are a key issue posing an obstacle to measles elimination. This study aims to identify the gaps by estimating the age-stratified probability of seropositivity, and to ascertain a suitable age for the administration of a third dose of a measles-containing vaccine (MCV3) to effectively fill these gaps.
Methods: We retrospectively obtained measles serological results from hospital setting among among individuals aged 13-39 years and developed a serocatalytic dynamic probability model, stratifying seropositivity due to vaccination or natural infection.
Background: A next-generation, serum-free, highly purified Vero cell rabies vaccine, PVRV-NG2, is in development.
Methods: This multicenter, observer-blind, phase 3 study evaluated the immunogenicity and safety of PVRV-NG2, compared with two licensed rabies vaccines (purified Vero cell rabies vaccine [PVRV] and human diploid cell vaccine [HDCV]), as a pre-exposure prophylaxis (PrEP) regimen. Participants were randomized 3:1:1 to PVRV-NG2, PVRV, or HDCV, as a three-dose (Cohort 1; children and adults; day [D] 0, D7, and D28) or two-dose (Cohort 2; adults; D0 and D7) PrEP regimen.
Immunogenicity and safety of tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis in immunocompromised 20 to <40 kg children and adolescents: A pilot, prospective, open-labeled study.
Hum Vaccin Immunother
December 2024
Article Synopsis
- A study was conducted to assess the effectiveness of Tixagevimab-Cilgavimab in immunocompromised children and adolescents weighing between 20 to >40 kg, with two different dosage groups based on weight (300 mg for 20 to <40 kg and 600 mg for ≥40 kg).
- After measuring antibody levels at multiple time points, results showed that both dosages produced high levels of neutralizing antibodies against the ancestral SARS-CoV-2 strain, significantly surpassing levels in healthy children who had received three BNT162b2 vaccinations.
- Adverse effects were mild and slightly more common in the heavier dosage group; overall, the study concluded that the lower dosage was just as effective as the higher
This sub-study sought to characterize the pharmacokinetics (PK) of favipiravir (FPV) within Thai adults and quantitatively assess differences in exposure to those previously reported in other populations as a basis to understand putative differences in efficacy between studies conducted in different regions. It was nested within a prospective trial of adults with symptomatic COVID-19 infection without pneumonia receiving 1800 mg FPV twice-daily on day 1 and 800 mg twice-daily thereafter. Individual PK profiles were fitted with a one-compartment disposition model (first-order absorption).
View Article and Find Full Text PDFObjective: We described mortality and loss to follow-up (LTFU) in children and adolescents who were under care for more than 5 years following initiation of antiretroviral therapy (ART).
Methods: Patients were followed from 5 years after ART until the earlier of their 25th birthday, last visit, death, or LTFU. We used Cox regression to assess predictors of mortality and competing risk regression to assess factors associated with LTFU.